Drug Trial Radar · NCT07726433
Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV
Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Jun 1, 2028
Study completion Jun 1, 2028
Sponsor
- Lead sponsor
- Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, single-arm, multicenter, exploratory clinical trial divided into a screening phase, a treatment phase, and a follow-up phase. The study aims to evaluate the efficacy and safety of foslorapitant palonosetron for injection in preventing nausea and vomiting caused by treatment with recanituzumab. All patients who meet the inclusion criteria and do not meet any exclusion criteria are eligible for enrollment in this study and are scheduled to receive targeted therapy, antiemetic treatment, and follow-up. Dosage Regimen Eligible subjects will receive a prophylactic antiemetic regimen consisting of foslorapitant and palonosetron. The dosage regimen is as follows: Day 1 (D1): Foslorapitant and palonosetron (218 mg foslorapitant and 0.25 mg palonosetron hydrochloride), administered intravenously (IV) 1 hour prior to chemotherapy. Observe for two treatment cycles (C1-C2); Starting from the first dose, record the patient's daily vomiting frequency, severity of nausea, and medication adherence.
Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
Fosrolapitant and Palonosetron Hydrochloride for InjectionDrug
D1: Fosrolapitant and Palonosetron Hydrochloride for Injection (218 mg of pholorapitant and 0.25 mg of palonosetron hydrochloride), IV, administered 1 hour before chemotherapy. Observe for two treatment cycles (C1-C2); Starting from the first dose, record the patient's daily vomiting frequency, severity of nausea, and medication adherence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Complete Response (CR) RateTime frame: 0 to 120 hours after trastuzumab rezetecan infusion within Cycle 1 and Cycle 2 (each treatment cycle is 21 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Cancer Hospital Airport Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.